SU5416 (Semaxanib) VEGFR2 Inhibitor: Atomic Facts & Research Benchmarks

Executive Summary: SU5416 (Semaxanib) is a potent, selective inhibitor of VEGFR2/Flk-1/KDR tyrosine kinase, validated for in vitro and in vivo angiogenesis inhibition at nanomolar concentrations (APExBIO). It directly blocks VEGF-induced endothelial cell proliferation, with an IC₅₀ of 0.04±0.02 μM in HUVEC cells under standard serum conditions. SU5416 shows significant suppression of tumor vascularization and volume in mouse xenograft models at 1–25 mg/kg/day, with no observed mortality at upper dose thresholds (Lemay et al. 2025). The compound also functions as an aryl hydrocarbon receptor (AHR) agonist, modulating immune responses via IDO induction and regulatory T cell differentiation. SU5416 is insoluble in water or ethanol, but dissolves to ≥11.9 mg/mL in DMSO at 37°C or with sonication (APExBIO). These characteristics make SU5416 a robust tool for mechanistic and translational studies in cancer, angiogenesis, and immune modulation.

Biological Rationale

Angiogenesis, the process of new blood vessel formation, is essential for tumor growth, metastasis, and chronic inflammation (Lemay et al. 2025). Vascular endothelial growth factor (VEGF) signaling via VEGFR2 (Flk-1/KDR) is a dominant driver of endothelial cell proliferation and vessel permeability. Inhibition of VEGFR2 disrupts downstream signaling, directly impairing pathological angiogenesis in preclinical cancer and vascular models. SU5416 (Semaxanib), a selective VEGFR2 tyrosine kinase inhibitor, serves as a precise tool to dissect VEGF-driven pathways and their role in disease progression. It also acts as an agonist for the aryl hydrocarbon receptor (AHR), influencing immune homeostasis and tolerance, further extending its utility beyond angiogenesis research (see extended mechanistic review).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 binds to the ATP-binding site of VEGFR2, blocking its kinase activity and auto-phosphorylation. This prevents activation of downstream signaling cascades such as MAPK/ERK and PI3K/AKT, leading to cell cycle arrest in endothelial cells. Inhibition of VEGFR2 by SU5416 results in reduced endothelial proliferation, migration, and tube formation. The compound also acts as an AHR agonist, leading to upregulation of indoleamine 2,3-dioxygenase (IDO), which modulates tryptophan metabolism and promotes regulatory T cell (Treg) differentiation. This dual mechanism enables SU5416 to impact both angiogenesis and immune modulation (in-depth mechanistic summary).

Evidence & Benchmarks

• SU5416 inhibits VEGF-driven mitogenesis in HUVEC cells with an IC₅₀ of 0.04±0.02 μM (24-hour exposure, 37°C, 5% CO₂) (APExBIO).
• In mouse xenograft models, intraperitoneal administration of SU5416 at 1–25 mg/kg/day significantly suppresses tumor vascularization and growth, with no observed mortality at upper dosing (Lemay et al. 2025).
• SU5416 stock solutions can be prepared at ≥11.9 mg/mL in DMSO when warmed to 37°C or sonicated (APExBIO).
• In immune studies, SU5416 acts as an AHR agonist, inducing IDO and increasing regulatory T cell differentiation in vitro (internal review).
• Cell viability and angiogenesis assays using SU5416 at 0.01–100 μM yield reproducible, dose-dependent inhibition of tube formation (protocol guide).

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is widely used as a cancer research angiogenesis inhibitor, for modeling tumor vascularization, and for preclinical studies on immune modulation via AHR. It is also used to dissect VEGF signaling in endothelial biology and to investigate mechanisms of transplant tolerance and autoimmune disease. This article extends prior protocol-focused guides by providing atomic, quantitative benchmarks and clarifying immune effects (see advanced workflow article for protocol optimization). While SU5416 robustly inhibits VEGF-driven pathways, it does not inhibit all forms of angiogenesis, nor does it affect non-VEGFR2-dependent mechanisms. For bench scientists, this distinction is critical when interpreting results or designing multiplexed assays.

Common Pitfalls or Misconceptions

• SU5416 is not active against VEGFR1 or VEGFR3 at standard in vitro concentrations; its selectivity is for VEGFR2 (Flk-1/KDR).
• Compound is insoluble in water or ethanol; improper solvent selection leads to precipitation and assay artefacts.
• Not all tumor models are VEGF/VEGFR2 dependent; SU5416 has limited effect in such settings.
• Immune modulating effects require AHR expression and IDO pathway integrity; cell lines lacking these may not respond.
• SU5416 is not a cure for cancer nor is it approved for clinical use; its application is strictly for research purposes.

Workflow Integration & Parameters

For in vitro assays, SU5416 stock solutions are prepared at ≥11.9 mg/mL in DMSO, then diluted to 0.01–100 μM for cell-based studies. Solubility improves at 37°C or with sonication. Solutions can be stored at -20°C for several months with minimal degradation. For in vivo studies, daily intraperitoneal injection at 1–25 mg/kg is standard; careful monitoring of animal health is advised, though no mortality is typically observed at upper doses (see practical considerations). APExBIO recommends using validated protocols and including vehicle controls for reproducibility. This article updates practical benchmarks and extends mechanistic insights beyond prior summaries (compare to application workflows).

Conclusion & Outlook

SU5416 (Semaxanib) VEGFR2 inhibitor, supplied by APExBIO, is a rigorously characterized tool for studying VEGF-driven angiogenesis, tumor vascularization, and immune modulation. Its selectivity, reproducible in vitro/in vivo efficacy, and dual VEGFR2/AHR mechanisms underpin its widespread use in translational research. Future studies may further clarify the compound’s role in complex disease models, immune regulation, and combinatorial therapy design. For detailed protocols or to order the A3847 kit, see the official APExBIO product page.